India’s Zydus Cadila mentioned on Wednesday its COVID-19 vaccine candidate was discovered to be secure and well-tolerated in an early-stage human trial.
The firm will now begin a mid-stage trial of the vaccine candidate, ZyCoV-D, in over 1,000 wholesome grownup volunteers from Thursday to check its effectiveness, it mentioned in a regulatory submitting.
Zydus plans to finish late-stage trials for ZyCoV-D by February or March and will produce as much as 100 million doses a 12 months initially, the corporate’s chairman informed Reuters final month.
The security of the vaccine candidate in volunteers enrolled within the early-stage trial, who had been administered doses since July 15, was endorsed by an unbiased information security monitoring board.
Zydus can also be among the many a number of Indian generic drugmakers which have licensing agreements with U.S.-based Gilead Sciences to supply remdesivir, the antiviral that has been accredited within the nation as an emergency remedy to struggle the coronavirus outbreak.
India reported a day by day leap of greater than 50,000 coronavirus infections for the seventh straight day on Wednesday. Total instances now stand at 1.91 million, the third largest, after the United States and Brazil.
(Except for the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)